Drug Profile
Research programme: small molecule therapeutics - Petra Pharma
Alternative Names: PETRA-01; PIP4K2 inhibitors - Petra Pharma; SB 02829Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Sprint Bioscience
- Developer Petra Pharma; Ravenna Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Metabolic disorders
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA
- 28 Oct 2021 No recent reports of development identified for research development in Metabolic-disorders in USA
- 08 Mar 2021 HiberCell acquires PIP4K2 inhibitors programme (PETRA-01) from Ravenna Pharmaceuticals